AxoGen, Inc. $AXGN Stock Holdings Increased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 7.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,869,955 shares of the medical equipment provider’s stock after acquiring an additional 190,557 shares during the period. Vanguard Group Inc. owned approximately 0.06% of AxoGen worth $93,934,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Aquatic Capital Management LLC raised its stake in AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 1,269 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in AxoGen during the 3rd quarter valued at $43,000. Tower Research Capital LLC TRC raised its stake in AxoGen by 189.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 3,327 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in AxoGen during the 3rd quarter valued at $64,000. Finally, State of Wyoming bought a new stake in AxoGen during the 2nd quarter valued at $69,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Stock Down 1.6%

AXGN opened at $40.29 on Thursday. AxoGen, Inc. has a one year low of $9.22 and a one year high of $45.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. The stock’s fifty day moving average is $34.97 and its 200-day moving average is $31.81. The company has a market capitalization of $2.14 billion, a PE ratio of -62.95 and a beta of 1.17.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to the consensus estimate of $57.85 million. AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%. On average, equities analysts predict that AxoGen, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on AXGN. Citizens Jmp boosted their price objective on AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Wednesday, April 29th. Lake Street Capital boosted their price objective on AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Raymond James Financial reissued an “outperform” rating and issued a $48.00 price objective on shares of AxoGen in a research note on Wednesday, April 29th. HC Wainwright boosted their price objective on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Citigroup reissued an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, AxoGen presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell sold 1,647 shares of AxoGen stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the transaction, the director directly owned 93,826 shares in the company, valued at $3,996,987.60. The trade was a 1.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Johnson sold 11,050 shares of AxoGen stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the transaction, the director owned 11,050 shares in the company, valued at $478,023. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 34,262 shares of company stock valued at $1,440,250. Insiders own 2.44% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.